LeonaBio, Inc.
LeonaBio, Inc. (LONA): 4 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.5 months
D/E 0.45 · 103% dilution
Lead: Phase 2/Phase 3
4 candidates
1 upcoming, next in ~653d
0 buys · 10 sells (180d)
A transparent, data-derived signal for LeonaBio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$79.4M
Cash
$32.8M
Quarterly Burn
$20.9M
Runway
9.5 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ath-1017 | Phase 2/Phase 3 |
| ath-1020 | Phase 2/Phase 3 |
| ath-1105 | Phase 2/Phase 3 |
| lasofoxifene | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
34
Total value held
$68.0M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 3,718,644 | $38.2M |
| adar1 capital management, llc | 727,481 | $7.5M |
| acorn capital advisors, llc | 634,539 | $6.5M |
| commodore capital lp | 464,398 | $4.8M |
| vanguard capital management llc | 389,520 | $4.0M |
| simplify asset management inc. | 149,279 | $1.5M |
| propel bio management, llc | 149,279 | $1.5M |
| geode capital management, llc | 80,323 | $826K |
| renaissance technologies llc | 64,222 | $660K |
| blackrock, inc. | 56,051 | $576K |
Showing top 10 of 34 institutional holders of LeonaBio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in LeonaBio, Inc.'s pipeline?
LeonaBio, Inc. (LONA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LeonaBio, Inc.'s lead drug candidate?
LeonaBio, Inc.'s most advanced tracked candidate is ath-1017 (Phase 2/Phase 3) for Alzheimer Disease.
What is LeonaBio, Inc.'s next catalyst?
LeonaBio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of" — expected April 1, 2028.
What is LeonaBio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LeonaBio, Inc. has approximately 9.5 months of cash runway.
What is LeonaBio, Inc.'s market capitalization?
LeonaBio, Inc.'s market capitalization is approximately $79.4M.
Get the full picture on LeonaBio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.